What is XELJANZ®?1
- XELJANZ® contains the active ingredient tofacitinib1
- XELJANZ® is the first-in-class of a new oral treatment that targets the Janus kinase (JAK) pathways2
- Excessive production of cytokines causes joint pain and symptoms through activation of the JAK pathways2
How to take XELJANZ®?1
Efficacy of XELJANZ®
An oral JAK inhibitor proven to deliver a powerful, rapid relief of joint pain caused by autoimmunity3
XELJANZ® offers a consistent safety profile
Consistent safety data with
* Please consult your doctor or your pharmacist for more information.